Natriumjodid (I-123) Curium Netherlands (Sodium Iodide (123 I))

After intravenous injection, the I-123 isotope is taken up by thyroid cells via the sodium‑iodide symporter. The radioactive decay of I-123 emits gamma photons that are captured by a gamma camera, producing detailed images that reflect the functional activity of the thyroid gland.

The administered activity of Sodium Iodide (I-123) is determined by the prescribing physician or nuclear medicine specialist based on the specific diagnostic protocol, patient size, and equipment sensitivity. Exact dosing is individualized and should follow local regulatory and institutional guidelines.

Sodium Iodide (I-123) should only be used in pregnancy when the diagnostic benefit justifies the potential radiation risk to the fetus. For breastfeeding mothers, temporary suspension of nursing or provision of expressed milk is recommended until the radioactivity has sufficiently cleared, as advised by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Compared with I-131, I-123 emits lower‑energy gamma photons, resulting in higher‑resolution images and reduced radiation dose to the patient. Unlike technetium‑99m pertechnetate, I-123 is actively organified within the thyroid, providing more accurate functional information for certain diagnostic scenarios.

The product must be stored refrigerated at 2‑8 °C, protected from light, and never frozen or shaken. It should be handled in a shielded environment by trained personnel, following radiation safety protocols to minimise exposure to staff and the environment.

Sodium Iodide (I-123) is administered intravenously as a sterile solution. The injection is performed by qualified healthcare professionals in a nuclear medicine suite, after confirming patient identity, baseline thyroid function and any contraindications.

Serious risks include allergic reactions that can progress to anaphylaxis, radiation‑induced thyroiditis, and severe hypotension. These events are rare but require immediate medical attention. Institutions should have emergency protocols and appropriate resuscitation equipment readily available.

Patients with known hypersensitivity to iodine‑based radiopharmaceuticals, those who have received high‑dose iodide therapy within the preceding 24 hours, or individuals for whom radiation exposure poses an unacceptable risk (e.g., certain pregnant patients) should not receive Sodium Iodide (I-123) unless a clear clinical benefit outweighs the risk.